drugset

drugset / Trial / NCT00573326

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

NCT00573326 ↗

Phase 2 Unknown 30 enrolled Azienda Ospedaliera Universitaria Policlinico Università Politecnica delle Marche · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to verify effect and tolerability of imatinib on pulmonary and skin fibrosis in patients affected by systemic sclerosis.

Timeline

Start: 2009-02
Primary completion: 2010-06
Completion: 2010-06

Publications

Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W, Corvetta A, Moroncini G, Gabrielli A; Imatinib in Scleroderma Italian Study Group. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014 Jul 8;16(4):R144. doi: 10.1186/ar4606.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	200 mg	Oral

Indications